Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $82.1 million.

  • Regenxbio's Operating Expenses fell 478.82% to $82.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.2 million, marking a year-over-year decrease of 422.76%. This contributed to the annual value of $316.7 million for FY2024, which is 1163.49% down from last year.
  • Latest data reveals that Regenxbio reported Operating Expenses of $82.1 million as of Q3 2025, which was down 478.82% from $84.6 million recorded in Q2 2025.
  • Regenxbio's 5-year Operating Expenses high stood at $97.6 million for Q3 2022, and its period low was $62.9 million during Q1 2021.
  • For the 5-year period, Regenxbio's Operating Expenses averaged around $84.5 million, with its median value being $85.3 million (2023).
  • In the last 5 years, Regenxbio's Operating Expenses surged by 4897.66% in 2022 and then plummeted by 1584.9% in 2024.
  • Quarter analysis of 5 years shows Regenxbio's Operating Expenses stood at $85.1 million in 2021, then rose by 4.77% to $89.1 million in 2022, then decreased by 3.37% to $86.1 million in 2023, then dropped by 15.72% to $72.6 million in 2024, then rose by 13.17% to $82.1 million in 2025.
  • Its Operating Expenses was $82.1 million in Q3 2025, compared to $84.6 million in Q2 2025 and $76.9 million in Q1 2025.